TY  - JOUR
AU  - Schettini, Francesco
AU  - Sobhani, Navid
AU  - Ianza, Anna
AU  - Triulzi, Tiziana
AU  - Molteni, Alfredo
AU  - Lazzari, Maria Chiara
AU  - Strina, Carla
AU  - Milani, Manuela
AU  - Corona, Silvia Paola
AU  - Sirico, Marianna
AU  - Bernocchi, Ottavia
AU  - Giudici, Fabiola
AU  - Cappelletti, Maria Rosaria
AU  - Ciruelos, Eva
AU  - Jerusalem, Guy
AU  - Loi, Sherine
AU  - Fox, Stephen B
AU  - Generali, Daniele
PY  - 2020
DO  - 10.1007/s10549-020-05856-3
UR  - https://hdl.handle.net/10668/25332
T2  - Breast cancer research and treatment
AB  - mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the...
LA  - en
KW  - Biomarker
KW  - Breast cancer
KW  - Everolimus
KW  - Hormone receptors
KW  - Immunomodulation
KW  - mTOR
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Breast Neoplasms
KW  - Endothelial Cells
KW  - Everolimus
KW  - Female
KW  - Hormones
KW  - Humans
KW  - Immune System
KW  - Receptor, ErbB-2
KW  - Retrospective Studies
TI  - Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
TY  - research article
VL  - 184
ER  -